The effect of oral and IV ramosetron on postoperative nausea and vomiting in patients undergoing gynecological laparoscopy with total intravenous anesthesia
- 162 Downloads
Ramosetron can be administered orally as well as intravenously. We investigated the effect of oral ramosetron on postoperative nausea and vomiting (PONV) in patients undergoing gynecological laparoscopy.
One hundred and twenty women were allocated randomly to one of three groups (n = 40 in each) to receive saline (control), 0.1 mg oral ramosetron (PO), or 0.3 mg IV ramosetron (IV). Total intravenous anesthesia (TIVA) with propofol and remifentanil was used in all patients.
The incidence of complete response (no PONV, no rescue) in the control, IV, and PO groups was: 65%, 90%, and 87.5%, respectively, during the first 1 h; and 67.5%, 87.5%, and 80%, respectively, during 1 to 24 h.
The effect of oral ramosetron 0.1 mg was comparable to that of IV ramosetron 0.3 mg on the prevention of PONV in women undergoing gynecological laparoscopy with TIVA. Both the oral and IV forms were effective at preventing PONV during the first 1 h after surgery.
Key wordsGynecological laparoscopy Postoperative nausea and vomiting Ramosetron
Unable to display preview. Download preview PDF.
- 9.Yano S, Makino K, Nakamura H, Kai Y, Morioka M, Hamada J, Kochi M, Kuratsu J. Comparative clinical study of the anti-emetic effects of oral ramosetron and injected granisetron in patients with malignant glioma undergoing ACNU chemotherapy. Neurol Med Chir (Tokyo). 2005;45:294–299.CrossRefGoogle Scholar
- 15.Lee HJ, Kwon JY, Shin SW, Kim CH, Baek SH, Baik SW, Kim HK, Kim KH. Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients. Eur J Anaesthesiol. 2008;25:756–762.PubMedCrossRefGoogle Scholar